Sugi Predict

Sugi Predict / Compounds / SCHEMBL4264484

SCHEMBL4264484

SCHEMBL4264484

CC1CC1(Cn1cnc2c(Sc3ccc([N+](=O)[O-])cc3)nc(N)nc21)OC(COC(=O)OC(C)(C)C)P(=O)(O)O

nearest known ligand 0.34

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.34
▸ SLC29A1 Q99808 2/20 0.33
▸ LMNA P02545 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ HK1 P19367 1/20 0.31
▸ HKDC1 Q2TB90 1/20 0.31
▸ ADORA2A P29274 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ HBB P68871 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4271091 0.91 CYP1A2 (0.35) CYP1A2SLC29A1LMNARAB9ACYP3A4
SCHEMBL4271729 0.91 CYP1A2 (0.35) CYP1A2SLC29A1LMNARAB9ACYP3A4
SCHEMBL4268504 0.90 HK1 (0.32) HK1HKDC1ADORA2ACYP2C19
SCHEMBL2906360 0.88 SLC29A1 (0.36) CYP1A2SLC29A1LMNARAB9ACYP3A4
SCHEMBL2937343 0.86 CYP1A2 (0.36) CYP1A2SLC29A1LMNARAB9ACYP3A4
SCHEMBL2908881 0.84 CYP1A2 (0.40) CYP1A2SLC29A1LMNARAB9ACYP3A4
SCHEMBL6053569 0.84 CYP1A2 (0.40) CYP1A2SLC29A1LMNARAB9ACYP3A4
SCHEMBL4264425 0.82 CYP1A2 (0.35) CYP1A2SLC29A1LMNARAB9ACYP3A4
SCHEMBL4266002 0.81 HK1 (0.34) SLC29A1HK1HKDC1ADORA2ACYP2C19
SCHEMBL2909404 0.81 CYP1A2 (0.34) CYP1A2SLC29A1LMNARAB9ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605147-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2009-10-20 — — US claimed
US-20060293284-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same CHO DONG-GYU 2006-12-28 — — US claimed
US-20060052346-A1 Nucleoside phosphonate derivatives useful in the treatment of HIV infections LG LIFE SCIENCES LTD. (KR) 2006-03-09 — — US claimed
US-7605147-B2 Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same LG LIFE SCIENCES LTD. (KR) 2009-10-20 — — US disclosed
US-20060293284-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same CHO DONG-GYU 2006-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052346-A1 Nucleoside phosphonate derivatives useful in the treatment of HIV infections PNP, TYMP, ENTPD5 CYP1A2 2149/4885SLC29A1 7/4885LMNA 3728/4885
US-20060293284-A1 Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same PNP, ITPA, MTAP CYP1A2 1553/4885SLC29A1 17/4885LMNA 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.